Taipei Exchange - Delayed Quote TWD

Great Novel Therapeutics Biotech & Medicals (7427.TWO)

Compare
32.70
-0.45
(-1.36%)
At close: January 22 at 2:59:59 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Chia-Nan Chen President & Chairman of the Board -- -- --
Yingzhang Huang Accounting Supervisor -- -- --

Great Novel Therapeutics Biotech & Medicals

No.508, Zhongxiao East Road
16th Floor-5 Section 7 Nangang District
Taipei City, 115
Taiwan
886 2 2785 1399 https://www.gntbm.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
19

Description

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.

Corporate Governance

Great Novel Therapeutics Biotech & Medicals’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.